Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 | P22894 | 19/20 | 0.81 |
| ▸ | MMP3 | P08254 | 12/20 | 0.81 |
| ▸ | POLB | P06746 | 1/20 | 0.75 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.75 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.75 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.75 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4308168 | 1.00 | MMP8 (0.81) | MMP8MMP3POLBAPOBEC3AAPOBEC3G | |
| SCHEMBL6889052 | 0.89 | MMP8 (0.66) | MMP8MMP3POLBAPOBEC3AAPOBEC3G | |
| SCHEMBL8346417 | 0.89 | MMP8 (0.84) | MMP8MMP3POLBAPOBEC3AAPOBEC3G | |
| SCHEMBL6889057 | 0.89 | MMP8 (0.66) | MMP8MMP3POLBAPOBEC3AAPOBEC3G | |
| SCHEMBL31685698 | 0.88 | MMP8 (0.76) | MMP8MMP3POLBAPOBEC3AAPOBEC3G | |
| SCHEMBL26616352 | 0.88 | MMP8 (0.76) | MMP8MMP3POLBAPOBEC3AAPOBEC3G | |
| SCHEMBL26616353 | 0.88 | MMP8 (0.76) | MMP8MMP3POLBAPOBEC3AAPOBEC3G | |
| SCHEMBL6010087 | 0.86 | MMP8 (0.82) | MMP8MMP3POLBAPOBEC3AAPOBEC3G | |
| SCHEMBL13856619 | 0.85 | POLB (0.72) | MMP8MMP3POLBAPOBEC3AAPOBEC3G | |
| SCHEMBL5960179 | 0.85 | POLB (0.69) | MMP8MMP3POLBAPOBEC3AAPOBEC3G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7060832-B2 | Nitrogen-containing fused heterocyclic carboxylic acids having an absolute configuration of “R” | TANABE SEIYAKU CO., LTD. (JP) | 2006-06-13 | — | — | US | claimed |
| EP-1236728-B1 | S-type 2-substituted hydroxy-2-indolinylbutyric ester compounds and process for preparation thereof | TANABE SEIYAKU CO (JP) | 2006-07-05 | — | — | EP | disclosed |
| US-7060832-B2 | Nitrogen-containing fused heterocyclic carboxylic acids having an absolute configuration of “R” | TANABE SEIYAKU CO., LTD. (JP) | 2006-06-13 | — | — | US | disclosed |
| EP-1528062-A2 | Process for the preparation of s-type 4-substituted hydroxypyranoindolidine compounds | TANABE SEIYAKU CO., LTD. (JP) | 2005-05-04 | — | — | EP | disclosed |
| US-6716983-B2 | S type 2-substituted hydroxy-2-indolidinylbutyric ester compounds and process for preparation thereof | TANABE SEIYAKU CO., LTD. (JP) | 2004-04-06 | — | — | US | disclosed |
| WO-2003074489-A1 | CYCLIC N-SUBSTITUTED ALPHA IMINOCARBOXYLIC ACIDS FOR SELECTIVELY INHIBITING COLLAGENASE | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-09-12 | — | — | WO | disclosed |
| EP-0845464-B1 | S type 2-substituted hydroxy-2-indolidinylbutyric ester compounds as intermediates for camptothecin derivatives | TANABE SEIYAKU CO (JP) | 2003-08-13 | — | — | EP | disclosed |
| US-20030135049-A1 | S type 2-substituted hydroxy-2-indolidinylbutyric ester compounds and process for preparation thereof | TANABE SEIYAKU CO., LTD. | 2003-07-17 | — | — | US | disclosed |
| US-20020161231-A1 | Stype 2-substituted hydroxy-2-indolidinylbutyric ester compounds and process for preparation thereof | TANABE SEIYAKU CO., LTD. | 2002-10-31 | — | — | US | disclosed |
| EP-1236728-A2 | S-type 2-substituted hydroxy-2-indolinylbutyric ester compounds and process for preparation thereof | TANABE SEIYAKU CO., LTD. (JP) | 2002-09-04 | — | — | EP | disclosed |
| US-6388078-B1 | CHEMICAL INTERMEDIATE FOR A CAMPTOTHECIN COMPOUND | TANABE SEIYAKU COMPANY, LIMITED (JP) | 2002-05-14 | — | — | US | disclosed |
| US-6277992-B1 | USEFUL AS AN INTERMEDIATE FOR PREPARING CAMPTOTHECIN DERIVATIVES HAVING ANTITUMOR ACTIVITIES | TANABE SEIYAKU CO., LTD. (JP) | 2001-08-21 | — | — | US | disclosed |
| US-6114529-A | USEFUL FOR PREPARING CAMPTOTHECIN DERIVATIVES HAVING ANTITUMOR ACTIVITIES | TANABE SEIYAKU CO., LTD. (JP) | 2000-09-05 | — | — | US | disclosed |
| US-6015901-A | INTERMEDIATES FOR ANTITUMOR AGENTS | TANABE SEIYAKU CO., LTD. (JP) | 2000-01-18 | — | — | US | disclosed |
| US-5932732-A | S type 2-substituted hydroxy-2-indolidinylbutyric ester compounds and process for preparation thereof | TANABE SEIYAKU CO., LTD. (JP) | 1999-08-03 | — | — | US | disclosed |
| EP-0845464-A2 | S type 2-substituted hydroxy-2-indolidinylbutyric ester compounds as intermediates for camptothecin derivatives | TANABE SEIYAKU CO., LTD. (JP) | 1998-06-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161231-A1 | Stype 2-substituted hydroxy-2-indolidinylbutyric ester compounds and process for preparation thereof | TOP2B, TOP2A, SI | MMP8 4636/4885MMP3 4487/4885POLB 208/4885 |
| US-20030135049-A1 | S type 2-substituted hydroxy-2-indolidinylbutyric ester compounds and process for preparation thereof | TOP2B, TOP2A, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | MMP8 4624/4885MMP3 4807/4885POLB 299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.